Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (26)	7/15/1998 9:28:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Watching it closely, grabbed a tiny amount already. There's an article, "Structural genomics: Bioinformatics in the driver's seat" in the new issue Nature Biotechnology. Haven't read it yet, but was planning to comment to some thread, somewhere, after I did. With the bid at 7, there's still a research premium of about $40 million. Given the lack of a collaboration with a big-time pharma and the time that has elapsed since the last collaboration was announced, it seems like it is susceptible to a bit more erosion. When even I start to think like this, you know the sector is in trouble. ;-) An acquaintance works there, and he thinks they're hot. He's relatively inexperienced, however.